Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi
{"title":"[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].","authors":"Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi","doi":"10.1701/4556.45580","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 9","pages":"530-535"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4556.45580","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.
期刊介绍:
Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.